Desos P, Lepagnol J M, Morain P, Lestage P, Cordi A A
Institut de Recherches Servier, Suresnes, France.
J Med Chem. 1996 Jan 5;39(1):197-206. doi: 10.1021/jm950323j.
Recently, we reported the synthesis of 3-(sulfonylamino)-2(1H)-quinolones, a new series of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)/kainate and N-methyl-D-aspartic acid (NMDA)/glycine antagonists. By exploring the structure-activity relationships (SAR) in this series, we were able to identify the 6,7-dinitro derivative 6 as a potent and balanced antagonist at both receptors. Unfortunately, compound 6 was devoid of in vivo activity in mice anticonvulsant testing. To overcome this critical limitation, new compounds bearing various acidic moieties at the 3-position of the quinolone skeleton were synthesized and evaluated. The SAR of these new analogues indicated that not all acidic groups are acceptable at the 3-position: A rank order of potency going from carboxylic approximately phosphonic > tetrazole > mercaptoacetic > hydroxamic >> other heterocyclic acids was defined. In addition, the selectivity between the AMPA/kainate and NMDA/glycine sites is dependent on the nature of the substitution (nitro > chloro for AMPA selectivity), its position (5,7- > 6,7-pattern for glycine selectivity), and the distance between the quinolone moiety and the heteroatom bearing the acidic hydrogen (the longer the distance the more AMPA selective the compound). Among these new AMPA antagonists, we have identified 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid (24c) as a water soluble and selective compound endowed with an appealing pharmacological profile. Compared with the reference AMPA antagonist NBQX, the phosphonic acid 24c is much less potent in vitro but almost equipotent in vivo in the audiogenic seizures model after intraperitoneal administration. Moreover, unlike NBQX, compound 24c is also active after oral administration. In the gerbil global ischemia model, compound 24c shows a neuroprotective effect at 10 mg/kg/ip, equivalent to the reference NBQX.
最近,我们报道了3-(磺酰氨基)-2(1H)-喹诺酮类化合物的合成,这是一系列新型的α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)/海人藻酸以及N-甲基-D-天冬氨酸(NMDA)/甘氨酸拮抗剂。通过探索该系列化合物的构效关系(SAR),我们确定6,7-二硝基衍生物6是这两种受体的强效且平衡的拮抗剂。遗憾的是,化合物6在小鼠抗惊厥试验中缺乏体内活性。为克服这一关键限制,我们合成并评估了喹诺酮骨架3位带有各种酸性基团的新化合物。这些新类似物的构效关系表明,并非所有酸性基团在3位都是可接受的:确定了效力的排序为羧酸>膦酸>四唑>巯基乙酸>异羟肟酸>其他杂环酸。此外,AMPA/海人藻酸位点与NMDA/甘氨酸位点之间的选择性取决于取代基的性质(硝基>氯,用于AMPA选择性)、其位置(5,7-模式>6,7-模式,用于甘氨酸选择性)以及喹诺酮部分与带有酸性氢的杂原子之间的距离(距离越长,化合物对AMPA的选择性越高)。在这些新的AMPA拮抗剂中,我们确定6,7-二氯-2(1H)-氧代喹啉-3-膦酸(24c)是一种水溶性且具有选择性的化合物,具有吸引人的药理学特性。与参考AMPA拮抗剂NBQX相比,膦酸24c在体外效力低得多,但在腹腔注射后的听源性惊厥模型中体内效力几乎相当。此外,与NBQX不同,化合物24c口服给药后也有活性。在沙土鼠全脑缺血模型中,化合物24c在10mg/kg腹腔注射时显示出神经保护作用,与参考药物NBQX相当。